Medicine News

• Avastin Phase III Study Shows Positive Results In Women With Advanced Ovarian Cancer
  Sat, 27 February 2010
  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy al ...
• U.S. Food And Drug Administration Approves Cayston(R) For The Improvement Of Respiratory ...
  Sat, 27 February 2010
  Gilead Sciences, Inc. (Nasdaq:GILD) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa)...
• Forest Laboratories Receives Decision From FDA For Supplemental New Drug Application For ...
  Sat, 27 February 2010
  Forest Laboratories, Inc. (NYSE: FRX) announced that the U.S. Food and Drug Administration (FDA) did not approve the additional indication for Bystolic(R) (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company's Supplemental New Drug Application (sNDA). Bystolic is currently ap ...
• CDC's Advisory Committee On Immunization Practices Recommends Pfizer's Prevnar 13? Vacci ...
  Sat, 27 February 2010
  Pfizer Inc (NYSE:PFE) announced that the United States Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) has recommended the use of Prevnar 13? (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) for healthy children aged 2 months through 59 months for ...
• Supelco(R) Introduces Breakthrough In Bioseparations Performance -- Ascentis(R) Express ...
  Sat, 27 February 2010
  Supelco, a division of Sigma-Aldrich (Nasdaq: SIAL), announced the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core? particle design...
• Vion Pharmaceuticals Receives Response From FDA On Special Protocol Assessment For Onrig ...
  Sat, 27 February 2010
  VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VIONQ) announced that it had received a response from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for its oncology therapeutic Onrigin? (laromustine) Injection...
• Startup Joins UCLA Tech Incubator To Develop Technologies For Drug Discovery, Screening
  Sat, 27 February 2010
  Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening. Ion channels are proteins in cell membranes that play a central role in generating and transmitting ...
• New Edition Of ASM Press Biotechnology Text Announced
  Sat, 27 February 2010
  Acclaimed by students and instructors, Molecular Biotechnology: Principles and Applications of Recombinant DNA is now in its fourth edition, bringing it thoroughly up to date with the latest findings and the latest industrial, agricultural, pharmaceutical, and biomedical applications...
• Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Tre ...
  Sat, 27 February 2010
  Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult pati ...
• Ferring Pharmaceuticals And Gene Security Network Partner To Test Advanced Preimplantati ...
  Fri, 26 February 2010
  Ferring Pharmaceuticals and Gene Security Network (GSN) announced that they have signed an agreement to conduct a clinical trial of GSN's advanced preimplantation genetic diagnosis (PGD) technology, Parental Support?. The 11-center U.S...